Director share sale disclosed by Evotec (EVO) in June 2026 filing

Rhea-AI Filing Summary

Evotec SE filed a Form 6-K as a foreign private issuer to report a directors’ dealing by Dr. Cord Dohrmann. The filing states that on June 16, 2026, the company submitted a directors’ dealing notice for a transaction in which Dr. Dohrmann sold shares, detailed in Exhibit 99.1. This is an administrative disclosure and does not include financial results or guidance.

Key Terms

Form 6-K, foreign private issuer, directors’ dealing, Form 20-F

4 terms

Form 6-K regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT RULE 13a-16 OR 15d-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

directors’ dealing financial

"submitted a directors’ dealing of Cord Dohrmann attached hereto as Exhibit 99.1"

Form 20-F regulatory

"whether the registrant files or will file annual reports under cover Form 20-F"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2026

COMMISSION FILE NUMBER 001-34041

Evotec SE
(Translation of registrant’s name into English)

Essener Bogen 7

22419 Hamburg

Germany

Tel: +49 40 560810
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On June 16, 2026, Evotec SE (the “Company”) submitted a directors’ dealing of Cord Dohrmann attached hereto as Exhibit 99.1.

EXHIBIT INDEX

Exhibit	Description of Exhibit
99.1	Directors’ dealing Dr. Cord Dohrmann, sell

SIGNATURE

Pursuant to the requirements, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Evotec SE
	By:	/s/ Christian Wojczewski
		Name: Christian Wojczewski
		Title: Chief Executive Officer

Date: June 17, 2026

Exhibit 99.1

Directors’ Dealings | 16 June 2026 17:46 Notification and public disclosure of transactions by persons discharging manageri responsibilities and persons closely associated with them 16.06.2026 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. 1. Details of the person discharging managerial responsibilities / person closely associated a) Name Title: Dr. First name: Cord Last name(s): Dohrmann 2. Reason for the notificati a) Position / status Position: Member of the managing body b) Initial notificati 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Evotec SE b) LEI 529900F9KI6OYITO9B12 4. Details of the transaction(s) Evotec SE Evotec SE: Dr. Cord Dohrmann, sell

a) Description of the financial instrument, type of instrument, identification Type: Share ISIN: DE0005664809 b) Nature of the transaction Disposal c) Price(s) and volume(s) Price(s) Volume(s) 4.81 EUR 576,720.00 EUR d) Aggregated information Price Aggregated volume 4.81 EUR 576,720.00 EUR e) Date of the transaction 15/06/2026; UTC+2 f) Place of the transaction Name: Xetra MIC: XETR 16.06.2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Language: English Company: Evotec SE Manfred Eigen Campus / Essener Bogen 7 22419 Hamburg Germany

Internet: www.evotec.com End of News EQS News Service 105568 16.06.2026 CET/CEST

FAQ

What did Evotec (EVO) disclose in its June 2026 Form 6-K?

Evotec SE disclosed that it submitted a directors’ dealing notice for Dr. Cord Dohrmann. The filing notes that the transaction involved a sale of shares and is detailed in Exhibit 99.1 attached to the report.

Who is involved in the directors’ dealing reported by Evotec (EVO)?

The directors’ dealing involves Dr. Cord Dohrmann. Evotec SE states that a dealing by Dr. Dohrmann was submitted as a directors’ dealing notice and attached as Exhibit 99.1 to the Form 6-K report.

What type of transaction did Evotec (EVO) report for Dr. Cord Dohrmann?

The Form 6-K indicates that Dr. Cord Dohrmann engaged in a sale transaction. The exhibit index describes Exhibit 99.1 as a directors’ dealing for Dr. Dohrmann with the notation “sell,” indicating a share sale.

Does Evotec’s June 2026 Form 6-K include earnings or financial results?

The June 2026 Form 6-K focuses on a directors’ dealing by Dr. Cord Dohrmann. It describes submission of a dealing notice and attaches it as Exhibit 99.1, without presenting earnings figures or broader financial performance data.

Under which reporting framework did Evotec (EVO) file this Form 6-K?

Evotec SE filed the report as a foreign private issuer that files annual reports on Form 20-F. The Form 6-K is submitted pursuant to Rules 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 4.4 KB